15 years of historical data (2010–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Processa Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $115M | $3M | $9M | $354M | $75M | $49M | $99M | $134M | $143M | $393470 | $629272 |
| Enterprise Value | $114M | $2M | $4M | $348M | $59M | $34M | $100M | $133M | $143M | $2M | $2M |
| P/E Ratio → | -0.56 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | 78.69 | 5.55 |
| P/B Ratio | 3.91 | 1.59 | 1.76 | 47.44 | 2.95 | 2.16 | 12.39 | 13.85 | 384.34 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | 400.51 | 17.58 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | 0.68 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -354.5% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | 72.4% | -11.0% |
| Operating Margin | — | — | — | — | — | — | — | — | — | -38430.4% | 2372.6% |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | -6719.6% | -2957.2% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -354.5% | -354.5% | -178.5% | -166.4% | -47.2% | -123.0% | -37.9% | -74.7% | -497.5% | — | — |
| ROA | -262.9% | -262.9% | -154.4% | -156.3% | -44.2% | -105.5% | -27.9% | -46.5% | -124.3% | -624.7% | -253.5% |
| ROIC | -1786.5% | -1786.5% | -1054.3% | -402.3% | -107.6% | -140.2% | -35.7% | -83.1% | — | — | 263.4% |
| ROCE | -356.9% | -356.9% | -180.7% | -166.2% | -49.0% | -89.9% | -35.4% | -69.9% | -1248.8% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $1M exceeds total debt of $73507, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.03 | 0.03 | 0.00 | 0.01 | 0.13 | 0.02 | 6.56 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 0.47 |
| Net Debt / Equity | — | -0.66 | -0.91 | -0.84 | -0.64 | -0.66 | 0.04 | -0.16 | -1.07 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 0.47 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -33518.07 | -53.84 | -107.36 | -28.07 | -50.50 | -7.83 | 11.42 |
Net cash position: cash ($1M) exceeds total debt ($73507)
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.22x means Processa Pharmaceuticals, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 8.40x to 1.22x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.22 | 1.22 | 7.71 | 8.40 | 18.87 | 13.27 | 0.85 | 3.13 | 1.14 | 0.03 | 0.05 |
| Quick Ratio | 1.22 | 1.22 | 7.71 | 8.40 | 18.87 | 13.27 | 0.85 | 3.13 | 1.14 | 0.03 | 0.05 |
| Cash Ratio | 0.78 | 0.78 | 6.44 | 6.51 | 16.99 | 12.63 | 0.58 | 2.70 | 1.10 | 0.03 | 0.00 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | 1.54 | 1.09 |
| Inventory Turnover | 0.52 | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Processa Pharmaceuticals, Inc. returns 0.0% to shareholders annually primarily through share buybacks.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.6% | 0.0% | 0.1% | 0.1% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.6% | 0.0% | 0.1% | 0.1% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $3M | $1M | $16M | $765973 | $374983 | $275868 | $266607 | $232826 | $11242 | $11237 |
Compare PCSA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| PCSAYou | $115M | -0.6 | — | — | — | — | -354.5% | -1786.5% | — |
| UTHR | $22B | 18.1 | 12.9 | 21.1 | 87.9% | 46.9% | 19.7% | 21.1% | — |
| ZLAB | $21B | -12.0 | — | — | 58.6% | -49.9% | -22.6% | -42.8% | — |
| AMRN | $6B | -3.5 | — | — | 35.6% | -40.2% | -15.8% | -18.7% | — |
| ALKS | $5B | 21.0 | 15.9 | 9571.4 | 86.3% | 17.2% | 14.7% | 14.9% | 0.2 |
| ADMA | $4B | 19.2 | 25.1 | 33.7 | 51.5% | 32.6% | 81.6% | 37.7% | 0.6 |
| ARQT | $3B | -207.5 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
| LQDA | $3B | -18.7 | — | — | 58.0% | -866.6% | -209.4% | -500.7% | — |
| SLGL | $3B | -241.3 | — | — | 98.0% | -104.1% | -31.4% | -41.5% | — |
| MLYS | $2B | -8.0 | — | — | — | — | -82.2% | -107.3% | — |
| ARDX | $2B | -25.2 | — | — | 90.3% | -10.1% | -36.2% | -10.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 15 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how PCSA stacks up against sector leader United Therapeutics Corporation.
Start ComparisonProcessa Pharmaceuticals, Inc.'s current P/E ratio is -0.6x. This places it at the 50th percentile of its historical range.
Processa Pharmaceuticals, Inc.'s return on equity (ROE) is -354.5%. The historical average is -174.8%.
Based on historical data, Processa Pharmaceuticals, Inc. is trading at a P/E of -0.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.